It looks like you're accessing our website from North America. We have a dedicated page tailored to your region, offering the most relevant information and services.
If you have an existing eCom account, you can log in to the North American site using your current username and password.
Would you like to visit the North America page?
You can access the page here
If you have any questions, please feel free to contact our support team hytest@hytest.fi
Glial fibrillary acidic protein (GFAP) is an astrocyte structural
protein. GFAP has been authorized as one of the biomarkers for mild
traumatic brain injury (mTBI) and its level shows a correlation with the
clinical severity after the injury.
Evaluate
GFAP MAbs
already today!
Read more and
order below!
GFAP is a member of the type III intermediate filament that provides
support and strength to cells and sustains the cell shape. In 2018,
GFAP, together with Ubiquitin C-terminal hydrolase-L1 (UCH-L1), received
approval as a biomarker for concussion in adults by the U.S. Food and
Drug Administration (FDA). This represented a great milestone in the
blood biomarker development for neurological disorders. Furthermore, it
can be detected in serum already within the first few hours after a head
injury.
Hytest offers several well-characterized monoclonal
antibodies that are specific to GFAP and which may be used for the
quantification of GFAP in serum, plasma, or CSF.
Learn more:
Cat# 4G25:Glial Fibrillary Acidic Protein, Antibody
Cat# 8G47: Glial fibrillary acidic protein (GFAP), human, recombinant
Copyright © 2025 Hytest Ltd.